Abstract
An unusual case of combined bronchial asthma and hypertrophic cardiomyopathy is described. She complained of precordial oppression, palpitation and dyspnea. These two diseases in this patient presented a paradoxy in terms of β-adrenergic therapy.
β-adrenergic antagonist was indicated for the treatment of hypertrophic cardiomyopathy, but it was contraindicated because of bronchial asthma.
We treated this patient with metroprolol, a recently developed selective β1-antagonist, for hypertrophic cardiomyopathy and salbutamol, a selective, β2-agonist, for bronchial asthma. Marked improvement in symptoms of palpitation and precardial oppression, findings of echocardiogram and phonocardiogram were obtained, without inducing asthmatic attacks or deterioration in pulmonary function.
We concluded that selective β1-antagonist combined with selective β2-agonist is useful in the treatment of patients with bronchial asthma associated with hypertrophic cardiomyopathy.
